Zymeworks Bc Inc.

Zymeworks Inc.

Surjit Bhimarao Dixit

Mario Sanches

Thomas Spreter Von Kreudenstein

Dunja Urosev

Stacey A L Tom-Yew

Adam Louis Corper

David Kai Poon

Igor Edmondo D'angelo

Paula Irene Lario

Gordon Yiu Kon Ng

Eric Escobar-Cabrera

Grant Raymond Wickman

Nina E Weisser

Dustin Weyland Blue Bleile

Martin J Boulanger

Michael Dl Suits

Yang-Chieh Chou

Igor Edmondo Paolo D'ANGELO

Igor Edmondo Paolo D'Angelo

Gregory Lakatos

Eric Escobar Cabrera

Siddharth Srinivasan

Gordon Yiu Ng

Stacey A Tom-Yew

Tomas Rodinger

Johannes Mullegger

Powell Patrick Cheng Tan

David Kai Yuen Poon

Gordon Yiukon Ng

The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the Cand/or Cdomains, one or more amino acid modifications in the Vand/or Vdomains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.

Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Modified antigen binding polypeptide constructs and uses thereof

Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

Bispecific antigen binding constructs targeting HER2

Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the Cand/or Cdomains, amino acid modifications in the Vand/or Vdomains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.

Bispecific antigen-binding constructs targeting HER2

Growing community of inventors

Richmond, Canada

Surjit Bhimarao Dixit